Yankees Score with ...
Health Care: Drugs
Advanced Cell Tech Inc. (ACTC: OTC)
$0.07 0.00 | 0.69%
05/24/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -28.53M | -72.80M | -54.37M | -36.76M |
| Operating Gains/Losses | 17.14K | 294.14K | 10.93M | 5.05M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -96.42K | 0.00 | 0.00 | 261.50K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 4.50M | 734.96K | 97.78K | -2.92M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 1.31M |
| (Increase) Decrease In Other Working Capital | 300.00K | 0.00 | 150.00K | 3.35M |
| Other Non-Cash Items | 8.49M | 57.35M | 21.90M | 17.71M |
| Net Cash From Continuing Operations | -14.61M | -13.63M | -8.78M | -5.14M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -14.61M | -13.63M | -8.78M | -5.14M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -96.26K | -36.83K | -207.40K | -5.37K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -15.09K | 0.00 | -12.60K | -2.17K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -111.35K | -36.83K | -220.00K | -7.54K |
| Issuance of Debt | 0.00 | 0.00 | 7.56M | 6.87M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 8.94M | 10.88M | 14.79M | 0.00 |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -84.55K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 8.86M | 10.88M | 22.35M | 6.87M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -5.86M | -2.79M | 13.35M | 1.72M |
Portfolios with ACTC
- Portfolio NameUser Type
- UserKJ Stocks
- UserMark
- UserBiotech88
- UserThe Jayden Project
- Userwright stocks
- UserRimp's Stockpicks
- UserMy Portfolio
- User2
- User1
- UserRAPTOR LAST 2
Latest ACTC Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 06.21.07 | 04:06 pm
Press Releases for ACTC
- Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day - PR Newswire 04.09.13 | 12:04 pm
- ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop - Business Wire 03.22.13 | 08:03 am
- Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials - Business Wire 03.14.13 | 08:03 am
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People On Stem Cells” - Business Wire 03.12.13 | 08:03 am
- Advanced Cell Technology To Present At BIO-Europe Spring 2013 - Business Wire 03.08.13 | 12:03 pm
- Advanced Cell Technology Announces Fourth-Quarter And Year-end Results - Business Wire 03.07.13 | 04:03 pm
- Advanced Cell Technology To Announce Fourth Quarter And Year-end Results On Thursday March 7th - Business Wire 03.04.13 | 09:03 am
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief Of BioResearch Open Access Journal - Business Wire 02.11.13 | 11:02 am
- ACT’s Clinical Partner Receives FDA Approval To Initiate Clinical Trial Using The Company’s HESC-derived Cells To Treat Severe Myopia - Business Wire 02.11.13 | 08:02 am
- Advanced Cell Technology To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.08.13 | 08:02 am
Partner Headlines for ACTC
- First patients picked for stem cell vision trials - Reuters 06.16.11 | 09:06 am
- UPDATE 3-US court backs federal embryonic stem cells funds - Reuters 04.29.11 | 02:04 pm
- FDA OKs second Advanced Cell stem cell trial - Reuters 01.03.11 | 11:01 am
- UPDATE 2-Second US company gets stem cell go-ahead - Reuters 11.22.10 | 02:11 pm
- UPDATE 3-First patient treated in Geron stem cell trial - Reuters 10.11.10 | 03:10 pm
- Geron given FDA go-ahead for stem cells trial - Financial Times 07.30.10 | 06:07 pm
